Global Telomere Diagnostics Life Length specializes in telomere diagnostics with proven platform (TAT®) and an in vitro and in vivo assay capability, offering potential cross-sell opportunities to biotechnology labs, CROs, and oncology research groups seeking aging, cancer prognosis, and personalized medicine biomarkers.

Prostate Cancer Biomarker Recently developed a biomarker for early detection of prostate cancer, authorized by AEMPS in Europe and CMS in the U.S., already market-ready in Europe, presenting a near-term product to expand sales in oncology diagnostics and companion testing with existing clinical partners.

Regulatory & Quality Lead With ISO 15189, CLIA, ISO 13485, AEMPS, and U.S. state licenses, Life Length demonstrates strong compliance credentials. This can reassure potential hospital networks, CROs, and diagnostic labs evaluating new biomarker tests and outsourcing partnerships.

Global Reach & Services Serving clients in more than 30 countries with in vivo and in vitro biomarker projects positions Life Length for international expansion, channel partnerships with CROs, academic collaborations, and cross-border clinical studies.

Strategic Growth Signals Significant funding traction and robust revenue figures indicate a scalable platform. Opportunities exist for tiered service engagements, licensing discussions, and co-development deals with pharma/biotech firms pursuing diagnostics, precision medicine, and preventive health solutions.